Search Results - "El Cheikh, J"

Inhibition of FLT3 in AML: a focus on sorafenib by Antar, A, Otrock, Z K, El-Cheikh, J, Kharfan-Dabaja, M A, Battipaglia, G, Mahfouz, R, Mohty, M, Bazarbachi, A

“…FMS-like tyrosine kinase 3 ( FLT3 ) is one of the most commonly mutated genes in AML. FLT3 is mutated in ~30% of patients with AML, either by internal tandem…”
Get full text

Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and ‘retreatment’ approaches in the era of novel agents by Mohty, B, El-Cheikh, J, Yakoub-Agha, I, Avet-Loiseau, H, Moreau, P, Mohty, M

“…Treatment of multiple myeloma has evolved over the last decade, most notably with the introduction of highly effective novel agents. It is now possible to aim…”
Get full text

Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma by El Cheikh, J, Massoud, R, Abudalle, I, Haffar, B, Mahfouz, R, Kharfan-Dabaja, M A, Jisr, T, Mougharbel, A, Ibrahim, A, Bazarbachi, A

Get full text

Low-dose 5-azacytidine as preventive therapy for relapse of AML and MDS following allogeneic HCT by El-Cheikh, J, Massoud, R, Fares, E, Kreidieh, N, Mahfouz, R, Charafeddine, M, Kharfan-Dabaja, M A, Bazarbachi, A

Get full text

Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party by Sobh, M, Michallet, M, Gahrton, G, Iacobelli, S, van Biezen, A, Schönland, S, Petersen, E, Schaap, N, Bonifazi, F, Volin, L, Meijer, E, Niederwieser, D, El-Cheikh, J, Tabrizi, R, Fegeux, N, Finke, J, Bunjes, D, Cornelissen, J, Einsele, H, Bruno, B, Potter, M, Fanin, R, Mohty, M, Garderet, L, Kröger, N

“…We describe the use and outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for multiple myeloma (MM) in Europe between January 1990 and…”
Get full text

The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT by Devillier, R, Crocchiolo, R, Castagna, L, Fürst, S, El Cheikh, J, Faucher, C, Prebet, T, Etienne, A, Chabannon, C, Vey, N, Esterni, B, Blaise, D

“…We previously reported that reduced intensity conditioning (RIC) regimen with fludarabine, BU and 2.5 mg/kg of rabbit anti-thymocyte globulin (r-ATG) was…”
Get full text

Risk factors of Ganciclovir-related neutropenia after allogeneic stem cell transplantation: a retrospective monocentre study on 547 patients by Venton, G., Crocchiolo, R., Fürst, S., Granata, A., Oudin, C., Faucher, C., Coso, D., Bouabdallah, R., Berger, P., Vey, N., Ladaique, P., Chabannon, C., Merlin, M. le, Blaise, D., El-Cheikh, J.

“…Cytomegalovirus (CMV) infection is a serious complication that may occur in the weeks or months following bone marrow transplantation. However, both…”
Get full text

Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas by Castagna, L, Bramanti, S, Furst, S, Giordano, L, Crocchiolo, R, Sarina, B, Mauro, E, Morabito, L, Bouabdallah, R, Coso, D, Balzarotti, M, Broussais, F, El-Cheikh, J, Stella, C C, Brusamolino, E, Blaise, D, Santoro, A

“…Allo-SCT is regularly performed in advanced lymphoma. Haploidentical family donors are a valuable source of hematopoietic stem cells and transplants from these…”
Get full text

Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44 ) and T (HLA-DR ) cells by Lioznov, M, El-Cheikh, J, Hoffmann, F, Hildebrandt, Y, Ayuk, F, Wolschke, C, Atanackovic, D, Schilling, G, Badbaran, A, Bacher, U, Fehse, B, Zander, A R, Blaise, D, Mohty, M, Kröger, N

“…We investigated efficacy and toxicity of lenalidomide in 24 heavily pretreated myeloma patients with a median age of 59 years (range: 37–70) and relapse after…”
Get full text

Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT by Battipaglia, G, Labopin, M, Candoni, A, Fanin, R, El Cheikh, J, Blaise, D, Michallet, M, Ruggeri, A, Contentin, N, Ribera, J M, Stadler, M, Sierra, J, von dem Borne, P A, Bloor, A, Socié, G, Nagler, A, Mohty, M

“…Gemtuzumab ozogamicin (GO) may increase the risk of sinusoidal obstruction syndrome (SOS) when used prior to allogeneic stem cell transplantation (HSCT). We…”
Get full text

Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML by Legrand, F, Le Floch, A-C, Granata, A, Fürst, S, Faucher, C, Lemarie, C, Harbi, S, Bramanti, S, Calmels, B, El-Cheikh, J, Chabannon, C, Weiller, P-J, Vey, N, Castagna, L, Blaise, D, Devillier, R

Get full text

Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation by Auner, H W, Szydlo, R, van Biezen, A, Iacobelli, S, Gahrton, G, Milpied, N, Volin, L, Janssen, J, Nguyen Quoc, S, Michallet, M, Schoemans, H, el Cheikh, J, Petersen, E, Guilhot, F, Schönland, S, Ahlberg, L, Morris, C, Garderet, L, de Witte, T, Kröger, N

“…Outcomes and prognostic factors of reduced intensity-conditioned allo-SCT (RIC allo-SCT) for multiple myeloma (MM) relapsing or progressing after prior…”
Get full text

Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide by Castagna, L, Bramanti, S, Furst, S, Giordano, L, Sarina, B, Crocchiolo, R, Cheikh, J El, Granata, A, Morabito, L, Mauro, E, Faucher, C, Mohty, B, Harbi, S, Devillier, R, Chabannon, C, Carlo-Stella, C, Santoro, A, Blaise, D

Get full text

The patient’s CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide by Crocchiolo, R, Castagna, L, Furst, S, Devillier, R, Sarina, B, Bramanti, S, El-Cheikh, J, Granata, A, Harbi, S, Morabito, L, Faucher, C, Rimondo, A, Girardi, D, Mohty, B, Calmels, B, Carlo-Stella, C, Chabannon, C, Bouabdallah, R, Santoro, A, Vey, N, Weiller, P J, Blaise, D

Get full text

T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes by Devillier, R, Bramanti, S, Fürst, S, Sarina, B, El-Cheikh, J, Crocchiolo, R, Granata, A, Chabannon, C, Morabito, L, Harbi, S, Faucher, C, Santoro, A, Weiller, P-J, Vey, N, Carlo-Stella, C, Castagna, L, Blaise, D

“…Unmanipulated haploidentical transplantation (Haplo-SCT) using post-transplantation cyclophosphamide (PT-Cy) represents an alternative for patients with…”
Get full text

Retrospective analysis of common scoring systems and outcome in patients older than 60 years treated with reduced-intensity conditioning regimen and alloSCT by Castagna, L, Fürst, S, Marchetti, N, El Cheikh, J, Faucher, C, Mohty, M, Bouabdallah, R, Vey, N, Stoppa, A M, Esterni, B, Blaise, D

“…In this retrospective study, 63 patients >60 years with hematological malignancies and treated with allo-SCT and with reduced-intensity conditioning (RIC) were…”
Get full text

Effect of graft source on mismatched unrelated donor hemopoietic stem cell transplantation after reduced intensity conditioning by Malard, F, Fürst, S, Loirat, M, Chevallier, P, El-Cheikh, J, Guillaume, T, Delaunay, J, Le Gouill, S, Moreau, P, Blaise, D, Mohty, M

“…This retrospective report compared the results of graft source on outcome after allogeneic stem cell transplantation (allo-SCT) in patients with hematologic…”
Get full text

Rituximab as salvage therapy for refractory chronic GVHD by Mohty, M, Marchetti, N, El-Cheikh, J, Faucher, C, Fürst, S, Blaise, D

Get full text

Disease status is a more reliable predictive factor than histology in lymphoma patients after reduced-intensity conditioning regimen and allo-SCT by Castagna, L, Boubdallah, R, Furst, S, Coso, D, El Cheikh, J, Faucher, C, Crocchiolo, R, Granata, A, Chabannon, C, Lemarié, C, Calmels, B, Boher, J M, Mohty, M, Blaise, D

“…We analyzed 113 patients with lymphoma who underwent allogeneic transplantation with reduced-intensity conditioning (allo-RIC) regimens at a single…”
Get full text

Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a 'donor' versus 'no donor' comparison by Mohty, M, de Lavallade, H, El-Cheikh, J, Ladaique, P, Faucher, C, Fürst, S, Vey, N, Coso, D, Stoppa, A-M, Gastaut, J-A, Chabannon, C, Blaise, D

Get full text